Biosimilar Contract Manufacturing Market To Reach $25.19 Billion By 2033

Biosimilar Contract Manufacturing Market Growth & Trends

The global biosimilar contract manufacturing market size is expected to reach USD 25.19 Billion by 2033, registering a CAGR of 13.87% from 2025 to 2033, according to a new report by Grand View Research, Inc. Growing demand for low-cost therapeutics and the increasing prevalence of diseases, such as cancer, autoimmune disorders, blood disorders, and other diseases are the major factors driving the industry. In recent years, the approvals for biosimilar drugs have increased. For instance, in August 2022, the U.S. FDA approved Coherus’ drug Cimerli as an interchangeable biosimilar for Lucentis.

This biosimilar is used in treating ophthalmology conditions, such as Diabetic Macular Edema (DME), Macular Edema following Retinal Vein Occlusion (RVO), Neovascular (wet) Age-Related Macular Degeneration (AMD) Diabetic Retinopathy (DR), and Myopic Choroidal Neovascularization (mCNV). A growing number of biosimilar approvals are expected to profit the industry post-pandemic. There has been a rise in the number of biologics losing patents. For instance, biologics, such as Humira, Eylea, Keytruda, Stelara, Revlimid, and Eliquis, are expected to lose patents by 2030. The growing number of biologics losing patents is expected to promote the demand for biosimilars, thus promoting industry growth.

A significant number of small- and medium-sized biopharmaceutical companies lack infrastructure for manufacturing biosimilars. Furthermore, big pharmaceutical companies try to focus on their core competencies, such as research and marketing, owing to which they outsource manufacturing services. Such factors are further expected to promote industry growth to a great extent. Cancer is one of the major causes of death worldwide. The estimates of Cancer Tomorrow state that cancer is expected to affect 30.2 million people by 2040. The rising burden of the disease and the high cost of drugs are expected to promote the demand for low-cost biosimilars. This is likely to improve the manufacturing of cancer biosimilar in the post-pandemic period.

 Request a free sample copy or view the report summary: Biosimilar Contract Manufacturing Market Report

Biosimilar Contract Manufacturing Market Report Highlights

• The mammalian expression system represented the largest segment, with a share of 58% in 2024, owing to its ability to produce complex proteins with proper folding and post-translational modifications.

• The rheumatoid arthritis segment accounted for the largest revenue market share. The high global prevalence of rheumatoid arthritis, coupled with escalating treatment costs of reference biologics such as adalimumab, infliximab, and etanercept, has intensified the demand for biosimilars.

• The recombinant non-glycosylated proteins segment held the largest revenue share in the biosimilar contract manufacturing market in 2024, due to its streamlined production processes, lower manufacturing costs, and broad therapeutic applications, including insulin, growth hormones, and cytokines.

• The recombinant glycosylated proteins segment is the fastest-growing, fueled by rising demand for complex therapeutic biologics such as monoclonal antibodies and erythropoietin.

• Veterinary hospitals and clinics represent the largest segment in the Biosimilar Contract Manufacturings market, owing to their critical role in administering sedatives for surgical procedures, diagnostics, and routine animal care.

• North America biosimilar contract manufacturing market held the largest revenue share of 34.70% in 2024, driven by rising demand for cost-efficient biosimilar production, growing biopharmaceutical companies, and expanding strategic collaborations enhancing accessibility and affordability.

Biosimilar Contract Manufacturing Market Segmentation

Grand View Research has segmented the global biosimilar contract manufacturing market report based on source, service, therapeutic area, and region:

Biosimilar Contract Manufacturing Source Outlook (Revenue, USD Million, 2021 - 2033)

• Mammalian

• Non-mammalian

Biosimilar Contract Manufacturing Service Outlook (Revenue, USD Million, 2021 - 2033)

• Recombinant Non-glycosylated Proteins

• Recombinant Glycosylated Proteins

Biosimilar Contract Manufacturing Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)

• Oncology

• Blood Disorders

• Growth Hormonal Deficiency

• Chronic & Autoimmune Disorders

• Rheumatoid Arthritis

• Others

Biosimilar Contract Manufacturing Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • India

  • China

  • Japan

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

  • Oman

  • Qatar

List of Key Players in the Biosimilar Contract Manufacturing Market

• Boehringer Ingelheim GmbH

• Lonza

• Catalent, Inc.

• Rentschler Biopharma SE

• AGC Biologics

• ProBioGen

• FUJIFILM Diosynth Biotechnologies

• Toyobo Co. Ltd.

• Samsung Biologics

• Thermo Fisher Scientific, Inc.

• Binex Co., Ltd.

• WuXi Biologics

• AbbVie, Inc.

• ADMA Biologics, Inc.

• Cambrex Corporation

• Pfizer Inc.

• Siegfried Holding AG